

Speeding up enzyme discovery and engineering with ultrahigh-throughput methods

Hans Adrian Bunzel^{1,2}, Xavier Garrabou^{1,2}, Moritz Pott^{1,2}, Donald Hilvert¹

¹Laboratory of Organic Chemistry, ETH Zurich, Zurich CH-8093, Switzerland

Corresponding author: Hilvert, Donald hilvert@org.chem.ethz.ch

²H.A.B, X.G. and M.P. contributed equally to this work.

Abstract

Exploring the sequence space of enzyme catalysts is ultimately a numbers game. Ultrahigh-throughput screening methods for rapid analysis of millions of variants are therefore increasingly important for analyzing sequence-function relationships, searching large metagenomic libraries for interesting activities, and accelerating enzyme evolution in the laboratory. Recent applications of such technologies are reviewed here, with a particular focus on the practical benefits of droplet-based microfluidics for the directed evolution of natural and artificial enzymes. Broader implementation of such rapid, cost-effective screening technologies is likely to redefine the way enzymes are studied and engineered for academic and industrial purposes.

Introduction


Enzymes have found application as efficient and highly selective catalysts in manifold fields of chemistry and biology. The development of successful biocatalytic processes depends on the identification of a suitable catalyst for the reaction of interest and, if necessary, subsequent engineering of its properties. Genomic databases represent a valuable source of enzymes for chemical transformations important in cellular metabolism. Alternatively, viable candidates may be discovered by searching strain collections or metagenomic libraries. If a natural catalyst does not exist, for example for an abiological reaction, other strategies are necessary. One possibility is to redesign an existing enzyme, capitalizing on its inherently promiscuous catalytic abilities. Another is to create an artificial enzyme *de novo*, for example by computational design.

Once an appropriate starting point has been identified, it may require refinement to optimize its catalytic properties or to meet specific process needs. Directed evolution, which entails iterative rounds of genetic diversification and phenotypic screening or selection, has emerged as a particularly powerful tool for shaping protein properties in the laboratory. Specific activity, stability, substrate scope, and stereoselectivity of enzymes can be optimized using this technique.

Enzyme discovery and development both depend critically on efficient methods for identifying variants with desirable properties. Screening methods for monitoring reactions directly or through coupled assays are especially versatile in this regard, and have been used to tailor diverse enzymes for synthetic, pharmaceutical and therapeutic applications [1]. Because such methods are typically time-consuming and laborious, however, they may not match well with the pace of business [2]. In order to speed up screening campaigns, new technologies with substantially enhanced throughput have been developed [3-5]. In this review, we appraise the impact of ultrahigh-throughput screening platforms, particularly droplet-based microfluidics, on the operational study, selection, and engineering of enzyme function (Figure 1).

41

42 **Figure 1**



43

Medium and ultrahigh-throughput screening assays. The increased throughput of droplet-based microfluidics enables more efficient exploration of fitness landscapes during directed evolution than is possible with conventional microtiter plate assays.

47 **Increasing screening throughput**

48 Successful screening of large pools of variants to identify effective enzymes requires a robust link
49 between genotype and phenotype. The simplest way to establish such a connection is to
50 compartmentalize variants separately in the wells of microtiter plates, which serve as reaction
51 chambers that can be individually monitored by chromatography, spectroscopy or mass
52 spectrometry. Using conventional equipment, hundreds to thousands of variants may be screened
53 per experiment, and throughput can be substantially increased by robotic automatization.
54 Nevertheless, screening is usually the most time- and labor-intensive step in biocatalyst discovery
55 and optimization. The large quantities of reagents and other consumables needed represent a
56 significant cost factor, as well.

57 Miniaturization of the reaction chambers can increase throughput substantially, and thus the
58 speed of a screening campaign, while reducing costs. Microtiter plates in 96-, 384- and 1536-well
59 formats, which are compatible with standard liquid handling systems, are available. By replacing
60 wells with microcapillaries, further miniaturization is possible. The GigaMatrix, for instance, has
61 100,000 capillaries per standard-sized plate and can be readily loaded through capillary forces by
62 soaking in a cell suspension [6]. However, the small volume of each capillary (~200 nL) introduces
63 new challenges associated with evaporation, aeration, and extraction of active clones from specific
64 wells. Sample recovery becomes even more problematic upon further miniaturization. For
65 lithographic microchips containing up to 340,000 wells per cm², for example, variants are manually
66 extracted with toothpicks under a microscope [7].

67 Capillary-based approaches have been recently improved through the development of
68 microcapillary single-cell analysis and laser extraction (μ SCALE) [8 ● ●]. The μ SCALE platform utilizes
69 chips containing 10⁶ microcapillaries that can be readily loaded with a cell suspension and read out
70 by fluorescence microscopy. The aforementioned extraction challenges are solved by accurate
71 draining of individual capillaries with a laser pulse. In addition, volumes as small as 100 pL improve
72 the detection limit by increasing the effective concentration of single cells in the capillaries. However,

73 μ SCALE, like other miniaturization approaches, is limited by the inability to manipulate individual
74 reaction chambers once they are loaded, for example to supply additional reagents. Nonetheless,
75 several promising applications, including evolution of a fluorescent protein biosensor and screening
76 of alkaline phosphatases libraries, have been reported using a μ SCALE prototype [8●●,9●],
77 highlighting the potential of this emerging technique.

78 Although wells and capillaries are the conceptually simplest way to link genotype and
79 phenotype, assay throughput typically does not exceed $\sim 10^6$ variants. Higher numbers can be
80 analyzed if screening is moved from a solid support to solution. For instance, intact cells can serve as
81 sortable reaction compartments that are readily analyzed by fluorescence-activated cell sorting
82 (FACS) [10,11]. Flow cytometers, which are widely available in many institutes, enable screening of
83 up to 10^8 variants per day. FACS has been successfully employed to switch enantioselectivity in
84 esterases [12], improve catalytic efficiency of peptidases [13,14] and a glutathione transferase [15],
85 and alter the substrate scope of aminoacyl-tRNA synthetases [16] and non-ribosomal peptide
86 synthetases [17]. Though efficient, this approach requires non-toxic fluorogenic substrates that
87 either readily diffuse into the cell and become trapped upon reaction, or that are tethered to the cell
88 surface to link genotype and phenotype. As an alternative, it is possible to sort enzymes
89 encapsulated together with their encoding DNA and a fluorogenic substrate in hydrogel beads
90 stabilized by a polyelectrolyte shell [18●●]. This approach has been successfully employed to
91 evolve a phosphotriesterase in the laboratory.

92

93 **Droplet-based screening platforms**

94 A different approach to in-solution miniaturization relies on *in vitro* compartmentalization (IVC) of
95 mutant libraries and reagents within surfactant-stabilized micron-sized droplets in emulsions [19].
96 Here, the droplet serves as the reaction chamber, and its integrity ensures the genotype-phenotype
97 link. Active variants can be enriched by sorting water-oil-water double emulsions with conventional
98 FACS instruments. Thiolactonases [20], galactosidases [21], cellulases [22], and other hydrolases

[23 ●,24] have been successfully evolved in this way. Because common emulsification strategies lead to polydisperse droplet populations, the relationship between activity and readout is variable and the detection of hits is therefore problematic.

The advent of microfluidic technologies has greatly expanded the utility of IVC. Droplet-based microfluidics enables production of large numbers ($\sim 10^8$) of monodisperse droplets at very high


rates by continuous flow on chip [25]. Sophisticated manipulations such as droplet fusion, incubation, mixing, splitting, and sorting are also possible [26]. As a consequence, droplet-based microfluidics has become a powerful tool for analyzing and manipulating enzymes encapsulated within pico- or nanoliter droplets, combining the versatility of traditional microtiter plate-screening with the high throughput accomplished by FACS. Moreover, the tiny volumes involved reduce the costs of screening a single clone, as well as the waste generated, by as much as a million fold compared to automatized microtiter-plate screening [26].

Various methods are available for compartmentalizing enzyme libraries in droplets. In one modality, the catalyst variants are biosynthesized directly from their encoding genes by *in vitro* transcription and translation [27], eliminating bottlenecks associated with cellular transformation efficiencies. Alternatively, they may be produced *in vivo* by encapsulated host organisms. Depending on the protein and the assay, the enzymes can be secreted, displayed on the cell surface, or produced cytosolically. The substrate is either co-encapsulated with the host cell or added at a later time point by droplet fusion [28] or picoinjection [29]. If the cells do not take up the substrate, they can be lysed enzymatically [30], electrically [31] or by heating [32 ●] directly in the droplets to free the catalyst.

120 As for all miniaturized reaction chambers, sensitive detection methods are the key to success.
121 These are usually based on changes in fluorescence (Figure 2). For instance, fluorophores have been
122 activated by enzymatic oxidation [25,33], hydrolysis [30,34●,35,36●], and retro-aldol cleavage
123 [37●,38●●]. In addition, removal or displacement of a quencher by proteases [39,40],
124 polymerases [32●], RNAses [41], or glycosidases [42] has afforded fluorescent readouts. Finally,
125 coupled assays can be employed to detect the activity of enzymes such as glycosidases [43] and
126 dehydrogenases [44●●] in droplets. To maintain the link between genotype and phenotype, the
127 fluorophore must be retained


Fluorophore activation

Peroxidase/
Laccase




[25,33]

Hydrolase



[30,34 ●, 35, 36 ●]

Aldolase



[37 ●, 38 ● ●]




Quencher release

Protease





[39,40]

Polymerase





[32 ●]

RNAse



[41]


Glycosidase



[42]


Coupled assays

Glycosidase



[43]

Dehydrogenase



[44 ● ●]

Reactions targeted with droplet-based microfluidics. The assays typically rely on direct activation of the fluorophore, release of a quencher, or coupled assays. Reactions can be monitored via a fluorescence (green) or absorbance (blue) readout.

132 in the droplet where it is produced [45,46]. Equipping it with charged or hydrophilic groups is
133 generally an effective means to minimize leakage [47,48]. Because droplets are quite stable,
134 enzymatic reactions can be monitored over timescales ranging from minutes to hours on-chip [49],
135 and up to days off-chip [50]. As a consequence, enzymes that vary by at least five orders of
136 magnitude in catalytic efficiency are assayable with this technique [25,37 ●].

137 Library enrichment is performed with efficient microfluidic fluorescence-activated droplet
138 sorters (FADS) that sort single cells compartmentalized in water-in-oil emulsion droplets by
139 dielectrophoresis at rates between 1,000 and 30,000 droplets per second [51]. The ultra-high
140 throughput of such devices enables screening of up to 10^9 variants in a day, outcompeting the
141 efficiency of robotic microtiter plate screening by several orders of magnitude. The sorted
142 populations are generally isolated in bulk, and the genetic information propagated either by
143 regrowth of the isolated active variants, if intact cells are assayed, or amplified by PCR and recloned,
144 if cell lysates are analyzed. To minimize false positives resulting from variable single-cell expression
145 levels or encapsulation of multiple cells per droplet, sorting is usually repeated two to three times to
146 ensure sufficient enrichment before individual variants are analyzed via conventional plate assays.
147 Owing to the efficiency of these procedures, screening no longer limits the pace of discovery in
148 favorable cases. Instead, DNA recovery after sorting, subsequent genetic diversification, and
149 downstream data analysis constitute more significant bottlenecks.

150 The recent development of a microfluidic absorbance-activated droplet sorter (AADS) has the
151 potential to extend the range of assays amenable to high-throughput screening considerably
152 [44 ● ●]. Although AADS currently has lower throughput (300 droplets per second) than FADS, and
153 requires more advanced chip manufacture, successful enrichment of active NAD^+ -dependent amino
154 acid dehydrogenases using a miniaturized coupled assay convincingly established the feasibility of
155 implementing widely used chromogenic assays in microfluidic workflows. Much effort is currently
156 invested in coupling droplet-based microfluidics with other label-free detection methods such as
157 electrochemical detection, mass spectrometry, and IR, Raman and NMR spectroscopy [26]. Rapid

determination of enzymatic stereoselectivity is of particular interest for the identification and development of synthetically useful biocatalysts. Recent work has shown that the selectivity of enzymatic chiral resolutions conducted in droplets containing a few hundred cells can be analyzed in chip-integrated electrophoretic systems, paving the way towards microfluidics-based evolution of stereoselective enzymes [52,53]. Successes in this arena promise to make droplet-based microfluidics a universally applicable screening platform.

Discovery, characterization and optimization of natural enzymes

By making rapid and efficient searches of sequence space possible, ultrahigh-throughput screening systems are uniquely suited to aid the discovery, characterization and engineering of enzymes (Figure 1). Enrichment of rare enzymes present in large populations of predominantly inactive proteins illustrates the practicality of such approaches. In one recent example, droplet-based microfluidics facilitated isolation of proficient natural sulfatases and phosphatases from a metagenomic library at a hit rate of only one in a million variants [34 ●]. In another, bacteria possessing elevated cellulase activity were similarly identified in libraries of uncultivated microorganisms [36 ●]. Encapsulation of the microorganisms in droplets circumvented the need for cumbersome cultivation of individual clones prior to assay. Moreover, the microfluidics screen afforded hits with broader diversity and higher activity than traditional plate assays.

When combined with next-generation sequencing, ultrahigh-throughput assays represent a powerful strategy for comprehensively analyzing sequence-function relationships in biopolymers [54 ● ●,55-60]. This approach has been used to map the activity of millions of glucosidase variants generated by error-prone PCR [54 ● ●]. The resulting fitness landscapes not only revealed patterns of mutational tolerance, but also identified previously unknown sites crucial for glycosidase function and facilitated discovery of mutations that enhanced enzyme thermostability. In addition to insights into intrinsic protein properties, such mutational scanning experiments can shed light on how proteins behave in cells and the effects of genetic variation in higher organisms [55]. They also aid

enzyme engineering by identifying potential mutagenesis hotspots as shown by the conversion of 4-oxalocrotonate tautomerase into two enantiocomplementary 'Michaelases' [56]. In addition, mutational scanning by microfluidics offers a rapid means of generating neutral drift libraries [61]. Neutral drift libraries may in turn lead to discovery of novel activities and selectivities, as was shown in studies on serum paraoxonase [62] and a cytochrome P450 [63].

The ability to screen large libraries of variants is particularly valuable for refinement of enzymatic activities and selectivities by directed evolution. The number of possible protein variants is essentially unlimited, so strategies that increase the likelihood of identifying rare but desirable clones constitutes a major advantage. Exhaustive screening of libraries in which multiple residues are simultaneously randomized increases the chances of discovering both epistatic and synergistic mutations that are typically missed in medium-throughput assays [64]. Although significant rate accelerations have been achieved by iterative saturation mutagenesis using small subsets of proteinogenic amino acids to reduce combinatorial complexity [65], four to five residues can be completely randomized and exhaustively assayed with droplet-based microfluidics [37●,38●●]. Iteration of this process can be expected to lead to large evolutionary leaps. In principle, alternative evolutionary trajectories from one or more starting points can also be explored by this approach.

Identifying beneficial mutations usually becomes increasingly difficult in later rounds of directed evolution. For example, efforts to evolve a promiscuous arylsulfatase to cleave a fluorogenic phosphonate ester using a conventional microtiter plate assay failed to yield any improved variants [30]. Increasing the throughput and screening millions of variants by microfluidics can sometimes rescue such stalled evolutionary trajectories. In the case of the arylsulfatase, two rounds of mutagenesis and microfluidic screening afforded variants with 6-fold higher phosphatase activity and a comparable improvement in expression. Other catalysts have similarly benefited from this approach, including a nearly diffusion-limited variant of horseradish peroxidase (10-fold improvement) [25] and a ribozyme with RNase activity (28-fold improvement) [41]. In the latter case,

screening under multiple turnover conditions using droplet-based microfluidics proved superior to conventional SELEX (systematic evolution of ligands by exponential enrichment) experiments.

Optimizing computationally designed enzymes


Enhancing promiscuous activities by directed evolution has produced a broad repertoire of enzymes with abiological function. Creating artificial enzymes *de novo* with made-to-order activity is, in contrast, a far more challenging task. Over the last decade, biocatalysts for several abiological reactions have been created using computational tools to design enzymatic active sites and embed them in protein scaffolds [66]. Although the starting catalysts typically exhibit only modest activities, they are excellent starting points for directed evolution [67]. In favorable cases, computationally designed and experimentally optimized enzymes have achieved proficiencies matching those of natural enzymes [38 ● ●,68].

Evolving designed enzymes by conventional microtiter plate-based assays is a long, arduous process. For instance, seventeen rounds of evolution were necessary to create an artificial Kemp eliminase that accelerates a proton transfer reaction 6×10^8 fold [68]. Optimization of computationally designed Diels-Alderases [69], phosphoesterases [70] and (retro)aldolases [71,72] proved similarly difficult. Much speedier optimization is possible with high-throughput screening methods, as exemplified by a weakly active retro-aldolase [37 ●]. By exhaustively interrogating a significant fraction of the $(\beta\alpha)_8$ -barrel cavity by cassette mutagenesis, two different catalytic arrangements were identified in a single experiment that enhanced retro-aldolase activity up to 80-fold. The complementary stereoselectivity of these improved variants was also notable.

The large dynamic range of microfluidics-assisted assays makes improvement of already highly active variants possible as shown by the evolution of an artificial retro-aldolase with efficiency rivaling that of natural class I aldolases [38 ● ●]. The activity of the starting computational design was increased 4000-fold using a medium-throughput microtiter plate assay, but further gains proved elusive as beneficial mutations became increasingly rare after over thirteen rounds of evolution [71].

Subsequent microfluidic screening of large libraries prepared by targeted mutagenesis and error-prone PCR led to the identification of sixteen additional substitutions that boosted activity 30 fold to give a $>10^9$ -fold rate enhancement (Figure 3A) [38 ● ●]. In addition, unlike its progenitors, the resulting enzyme is a practical synthetic catalyst for asymmetric aldol additions of acetone to diverse electrophilic aldehydes (Figure 3B). Structural and mechanistic analyses suggest that its high activity and stereoselectivity can be ascribed to a constellation of four catalytic residues that emerged, one residue at a time, over the course of evolution [73]. Microfluidics screening will likely be useful for diversifying the promiscuous activities of this catalyst [74-77] and other *de novo* designed enzymes as well.

Figure 3



Directed evolution of a computationally designed aldolase using a droplet-based assay. A: Crystal structures of the starting design (A1), an evolutionary intermediate (A2), and the evolved aldolase RA95.5-8F (A3) represented in equivalent orientations. Key residues and a covalently bound mechanistic inhibitor are shown in stick representation. The catalytic residues of each variant are highlighted in yellow. B: Asymmetric aldol additions of acetone and aromatic (B1) or aliphatic (B2) aldehydes catalyzed by RA95.5-8F.

Perspective and future challenges

High-throughput strategies are revolutionizing the biological sciences. Today it is possible to synthesize and sequence DNA on a massively parallel scale. Large metagenomic libraries of microbial genomes found in nature are being created by directly extracting and cloning DNA from

environmental samples. And methods are available to diversify, in whole or in part, genes encoding specific natural and designed proteins to probe evolutionary relationships and alter or optimize biochemical function. Not surprisingly, comparable methods capable of exploring and exploiting this diversity, efficiently and in high-throughput, are increasingly vital. Powerful screening platforms based on microcapillaries and microfluidic devices have tellingly illustrated how new technologies can complement and extend traditional approaches for analyzing phenotype based on genetic selection or microtiter plate assays. In the future, commercialization of μ SCALE devices, droplet sorters and the like, as well as development of more flexible detection systems and invention of completely new ways to survey biological function on large scale will only enhance the accessibility, reliability, and affordability of such systems. High-throughput screening is destined to become an essential tool for any investigation of protein function.

Acknowledgments

Work in the authors' labs was supported by the Swiss National Science Foundation and the ETH Zurich.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- ● of outstanding interest

1. Bornscheuer UT, Huisman GW, Kazlauskas RJ, Lutz S, Moore JC, Robins K: **Engineering the third wave of biocatalysis**. *Nature* 2012, **485**:185-194.
2. Truppo MD: **Biocatalysis in the pharmaceutical industry: The need for speed**. *ACS Med Chem Lett* 2017, **8**:476-480.
3. Mair P, Gielen F, Hollfelder F: **Exploring sequence space in search of functional enzymes using microfluidic droplets**. *Curr Opin Chem Biol* 2017, **37**:137-144.
4. Longwell CK, Labanieh L, Cochran JR: **High-throughput screening technologies for enzyme engineering**. *Curr Opin Biotechnol* 2017, **48**:196-202.
5. Packer MS, Liu DR: **Methods for the directed evolution of proteins**. *Nat Rev Genet* 2015, **16**:379-394.

- 287 6. Lafferty M, Dyaico MJ: **GigaMatrix: A novel ultrahigh throughput protein optimization and**
288 **discovery platform.** *Methods Enzymol* 2004, **388**:119-134.
- 289 7. Ingham CJ, Sprengels A, Bomer J, Molenaar D, van den Berg A, van Hylckama Vlieg JET, de Vos WM:
290 **The micro-Petri dish, a million-well growth chip for the culture and high-throughput**
291 **screening of microorganisms.** *Proc Natl Acad Sci USA* 2007, **104**:18217-18222.
- 292 8. Chen B, Lim S, Kannan A, Alford SC, Sunden F, Herschlag D, Dimov IK, Baer TM, Cochran JR: **High-**
293 **● ● throughput analysis and protein engineering using microcapillary arrays.** *Nat Chem Biol*
294 2016,
295 **12**:76-81.
- 296 This paper describes a high-throughput screening system based on picoliter-sized capillaries arranged
297 on a chip that can be imaged with a confocal microscope and allows isolation of hits with a laser
298 pulse. The system was employed to screen for GFP expression, phosphatase activity, and peptide
299 binding with a throughput of 10^6 .
- 300 9. Lim S, Chen B, Kariolis MS, Dimov IK, Baer TM, Cochran JR: **Engineering high affinity protein-**
301 **protein**
302 **● interactions using a high-throughput microcapillary array platform.** *ACS Chem Biol* 2017,
303 **12**:336-341.
- 304 The affinity of a kinase domain for its target ligand was increased by high-throughput screening using
305 microcapillary single cell analysis and laser extraction (μ SCALE).
- 306 10. Yang G, Withers SG: **Ultrahigh-throughput FACS-based screening for directed enzyme evolution.**
307 *ChemBioChem* 2009, **10**:2704-2715.
- 308 11. Varadarajan N, Cantor JR, Georgiou G, Iverson BL: **Construction and flow cytometric screening of**
309 **targeted enzyme libraries.** *Nat Protoc* 2009, **4**:893-901.
- 310 12. Becker S, Hobenreich H, Vogel A, Knorr J, Wilhelm S, Rosenau F, Jaeger KE, Reetz MT, Kolmar H:
311 **Single-cell high-throughput screening to identify enantioselective hydrolytic enzymes.**
312 *Angew Chem Int Ed* 2008, **47**:5085-5088.
- 313 13. Francisco JA, Campbell R, Iverson BL, Georgiou G: **Production and fluorescence-activated cell**
314 **sorting of *Escherichia coli* expressing a functional antibody fragment on the external**
315 **surface.** *Proc Natl Acad Sci USA* 1993, **90**:10444-10448.
- 316 14. Chen I, Dorr BM, Liu DR: **A general strategy for the evolution of bond-forming enzymes using**
317 **yeast display.** *Proc Natl Acad Sci USA* 2011, **108**:11399-11404.
- 318 15. Griswold KE, Aiyappan NS, Iverson BL, Georgiou G: **The evolution of catalytic efficiency and**
319 **substrate promiscuity in human theta class 1-1 glutathione transferase.** *J Mol Biol* 2006,
320 **364**:400-410.
- 321 16. Santoro SW, Wang L, Herberich B, King DS, Schultz PG: **An efficient system for the evolution of**
322 **aminoacyl-tRNA synthetase specificity.** *Nat Biotech* 2002, **20**:1044-1048.
- 323 17. Niquille DL, Hansen DA, Mori T, Fercher D, Kries H., D. H: **Nonribosomal synthesis of backbone-**
324 **modified peptides.** *Nat Chem* 2017, DOI:10.1038/nchem.2891:in press.
- 325 18. Fischlechner M, Schaerli Y, Mohamed MF, Patil S, Abell C, Hollfelder F: **Evolution of enzyme**
326 **● ● catalysts caged in biomimetic gel-shell beads.** *Nat Chem* 2014, **6**:791-796.
- 327 A protocol is reported for the transformation of emulsion droplets into gel shell beads, which co-
328 localize an enzyme, its encoding gene and a fluorogenic substrate, thus allowing sorting with
329 conventional flow cytometers.
- 330 19. Tawfik DS, Griffiths AD: **Man-made cell-like compartments for molecular evolution.** *Nat Biotech*
331 1998, **16**:652-656.

- 332 20. Aharoni A, Amitai G, Bernath K, Magdassi S, Tawfik DS: **High-throughput screening of enzyme**
 333 **libraries: Thiolactonases evolved by fluorescence-activated sorting of single cells in**
 334 **emulsion compartments.** *Chem Biol* 2005, **12**:1281-1289.
- 335 21. Mastrobattista E, Taly V, Chanudet E, Treacy P, Kelly BT, Griffiths AD: **High-throughput screening**
 336 **of enzyme libraries: In vitro evolution of a β -galactosidase by fluorescence-activated**
 337 **sorting of double emulsions.** *Chem Biol* 2005, **12**:1291-1300.
- 338 22. Korfer G, Pitzler C, Vojcic L, Martinez R, Schwaneberg U: **In vitro flow cytometry-based screening**
 339 **platform for cellulase engineering.** *Sci Rep* 2016, **6**:26128.
- 340 23. Gupta RD, Goldsmith M, Ashani Y, Simo Y, Mullokandov G, Bar H, Ben-David M, Leader H,
 341 Margalit
 342 ● R, Silman I, et al.: **Directed evolution of hydrolases for prevention of G-type nerve agent**
 343 **intoxication.** *Nat Chem Biol* 2011, **7**:120-125.
 344 A phosphatase was subjected to directed evolution by simultaneous cassette mutagenesis of four
 345 residues and FACS screening. The best catalyst efficiently hydrolyzed nerve agents.
- 346 24. Griffiths AD, Tawfik DS: **Directed evolution of an extremely fast phosphotriesterase by in vitro**
 347 **compartmentalization.** *EMBO J* 2003, **22**:24-35.
- 348 25. Agresti JJ, Antipov E, Abate AR, Ahn K, Rowat AC, Baret JC, Marquez M, Klibanov AM, Griffiths AD,
 349 Weitz DA: **Ultrahigh-throughput screening in drop-based microfluidics for directed**
 350 **evolution.** *Proc Natl Acad Sci USA* 2010, **107**:4004-4009.
- 351 26. Dressler OJ, Solvas XCi, deMello AJ: **Chemical and biological dynamics using droplet-based**
 352 **microfluidics.** *Annu Rev Anal Chem* 2017, **10**:1-24.
- 353 27. Galinis R, Stonyte G, Kiseliovas V, Zilionis R, Studer S, Hilvert D, Janulaitis A, Mazutis L: **DNA**
 354 **nanoparticles for improved protein synthesis in vitro.** *Angew Chem Int Ed* 2016, **55**:3120-
 355 3123.
- 356 28. Mazutis L, Baret JC, Griffiths AD: **A fast and efficient microfluidic system for highly selective one-**
 357 **to-one droplet fusion.** *Lab Chip* 2009, **9**:2665-2672.
- 358 29. Beneyton T, Thomas S, Griffiths AD, Nicaud JM, Drevelle A, Rossignol T: **Droplet-based**
 359 **microfluidic high-throughput screening of heterologous enzymes secreted by the yeast**
 360 ***Yarrowia lipolytica*.** *Microb Cell Fact* 2017, **16**:18.
- 361 30. Kintsjes B, Hein C, Mohamed MF, Fischlechner M, Courtois F, Laine C, Hollfelder F: **Picoliter cell**
 362 **lysate assays in microfluidic droplet compartments for directed enzyme evolution.** *Chem*
 363 *Biol* 2012, **19**:1001-1009.
- 364 31. de Lange N, Tran TM, Abate AR: **Electrical lysis of cells for detergent-free droplet assays.**
 365 *Biomicrofluidics* 2016, **10**:024114.
- 366 32. Larsen AC, Dunn MR, Hatch A, Sau SP, Youngbull C, Chaput JC: **A general strategy for expanding**
 367 **● polymerase function by droplet microfluidics.** *Nat Commun* 2016, **7**:11235.
 368 Microfluidics was employed to evolve a polymerase to accept a non-natural substrate with high
 369 fidelity. The assay relies on displacement of a fluorescence-quencher-DNA adduct and could be used
 370 to evolve any polymerase.
- 371 33. Beneyton T, Coldren F, Baret JC, Griffiths AD, Taly V: **CotA laccase: High-throughput**
 372 **manipulation and analysis of recombinant enzyme libraries expressed in *E. coli* using**
 373 **droplet-based microfluidics.** *Analyst* 2014, **139**:3314-3323.
- 374 34. Colin PY, Kintsjes B, Gielen F, Miton CM, Fischer G, Mohamed MF, Hyvonen M, Morgavi DP,
 375 Janssen

376 ● DB, Hollfelder F: **Ultrahigh-throughput discovery of promiscuous enzymes by picodroplet**
 377 **functional metagenomics**. *Nat Commun* 2015, **6**:10008.

378 Ultrahigh-throughput screening was employed to isolate proficient phosphatases and sulfatases from
 379 a large metagenomic library. The high enrichment factors enabled efficient enrichment of rare
 380 variants.

381 35. Granieri L, Baret JC, Griffiths AD, Merten CA: **High-throughput screening of enzymes by retroviral**
 382 **display using droplet-based microfluidics**. *Chem Biol* 2010, **17**:229-235.

383 36. Najah M, Calbrix R, Mahendra-Wijaya IP, Beneyton T, Griffiths AD, Drevelle A: **Droplet-based**
 384 **● microfluidics platform for ultra-high-throughput bioprospecting of cellulolytic**
 385 **microorganisms**. *Chem Biol* 2014, **21**:1722-1732.

386 Ultrahigh-throughput screening was employed to isolate cellulases from a library of uncultivated
 387 bacteria. The high effective concentration of single cells in droplets allowed assessment of activity
 388 without prior cultivation.

389 37. Obexer R, Pott M, Zeymer C, Griffiths AD, Hilvert D: **Efficient laboratory evolution of**
 390 **● computationally designed enzymes with low starting activities using fluorescence-activated**
 391 **droplet sorting**. *Protein Eng Des Sel* 2016, **29**:355-366.

392 Divergent evolutionary trajectories of a computationally designed enzyme were examined by ultra-
 393 high throughput microfluidics screening. Despite low starting activity, significant rate accelerations
 394 and stereoselectivities were achieved in one or two steps.

395 38. Obexer R, Godina A, Garrabou X, Mittl PR, Baker D, Griffiths AD, Hilvert D: **Emergence of a**
 396 **catalytic**
 397 **● ● tetrad during evolution of a highly active artificial aldolase**. *Nat Chem* 2017, **9**:50-56.

398 A *de novo* designed retro-aldolase was evolved to rival the activity of natural aldolases using an
 399 ultrahigh-throughput microfluidics assay. The ability to screen large numbers of variants was key to
 400 improving a previously stalled evolutionary intermediate.

401 39. Ng EX, Miller MA, Jing T, Chen CH: **Single cell multiplexed assay for proteolytic activity using**
 402 **droplet microfluidics**. *Biosens Bioelectron* 2016, **81**:408-414.

403 40. Price AK, MacConnell AB, Paegel BM: **hnuSABR: Photochemical dose-response bead screening in**
 404 **droplets**. *Anal Chem* 2016, **88**:2904-2911.

405 41. Ryckelynck M, Baudrey S, Rick C, Marin A, Coldren F, Westhof E, Griffiths AD: **Using droplet-**
 406 **based microfluidics to improve the catalytic properties of RNA under multiple-turnover**
 407 **conditions**. *RNA* 2015, **21**:458-469.

408 42. Beneyton T, Wijaya IP, Postros P, Najah M, Leblond P, Couvent A, Mayot E, Griffiths AD, Drevelle
 409 A: **High-throughput screening of filamentous fungi using nanoliter-range droplet-based**
 410 **microfluidics**. *Sci Rep* 2016, **6**:27223.

411 43. Ostafe R, Prodanovic R, Lloyd Ung W, Weitz DA, Fischer R: **A high-throughput cellulase screening**
 412 **system based on droplet microfluidics**. *Biomicrofluidics* 2014, **8**:041102.

413 44. Gielen F, Hours R, Emond S, Fischlechner M, Schell U, Hollfelder F: **Ultrahigh-throughput-directed**
 414 **● ● enzyme evolution by absorbance-activated droplet sorting (AADS)**. *Proc Natl Acad Sci USA*
 415 2016, **113**:E7383-e7389.

416 This paper describes an absorbance-based microfluidics screen that substantially extends the range
 417 of assays amenable to droplet sorting.

418 45. Gruner P, Riechers B, Semin B, Lim J, Johnston A, Short K, Baret JC: **Controlling molecular**
 419 **transport in minimal emulsions**. *Nat Commun* 2016, **7**:10392.

420 46. Debon AP, Wootton RC, Elvira KS: **Droplet confinement and leakage: Causes, underlying effects,**
 421 **and amelioration strategies**. *Biomicrofluidics* 2015, **9**:024119.

- 422 47. Fenneteau J, Chauvin D, Griffiths AD, Nizak C, Cossy J: **Synthesis of new hydrophilic rhodamine**
423 **based enzymatic substrates compatible with droplet-based microfluidic assays.** *Chem*
424 *Commun* 2017, **53**:5437-5440.
- 425 48. Woronoff G, El Harrak A, Mayot E, Schicke O, Miller OJ, Soumillon P, Griffiths AD, Ryckelynck M:
426 **New generation of amino coumarin methyl sulfonate-based fluorogenic substrates for**
427 **amidase assays in droplet-based microfluidic applications.** *Anal Chem* 2011, **83**:2852-2857.
- 428 49. Frenz L, Blank K, Brouzes E, Griffiths AD: **Reliable microfluidic on-chip incubation of droplets in**
429 **delay-lines.** *Lab Chip* 2009, **9**:1344-1348.
- 430 50. Holtze C, Rowat AC, Agresti JJ, Hutchison JB, Angile FE, Schmitz CHJ, Koster S, Duan H, Humphry
431 KJ, Scanga RA, et al.: **Biocompatible surfactants for water-in-fluorocarbon emulsions.** *Lab*
432 *Chip* 2008, **8**:1632-1639.
- 433 51. Sciambi A, Abate AR: **Accurate microfluidic sorting of droplets at 30 kHz.** *Lab Chip* 2015, **15**:47-
434 51.
- 435 52. Krone KM, Warias R, Ritter C, Li A, Acevedo-Rocha CG, Reetz MT, Belder D: **Analysis of**
436 **enantioselective biotransformations using a few hundred cells on an integrated**
437 **microfluidic chip.** *J Am Chem Soc* 2016, **138**:2102-2105.
- 438 53. Thurmann S, Lotter C, Heiland JJ, Chankvetadze B, Belder D: **Chip-based high-performance liquid**
439 **chromatography for high-speed enantioseparations.** *Anal Chem* 2015, **87**:5568-5576.
- 440 54. Romero PA, Tran TM, Abate AR: **Dissecting enzyme function with microfluidic-based deep**
441 **● ● mutational scanning.** *Proc Natl Acad Sci USA* 2015, **112**:7159-7164.
442 The fitness landscape of a glucosidase was mapped by combining microfluidics screening and next
443 generation sequencing. The mutational scanning experiment revealed potential mutagenesis
444 hotspots as well as structurally and mechanistically conserved residues.
- 445 55. Fowler DM, Fields S: **Deep mutational scanning: A new style of protein science.** *Nat Methods*
446 2014, **11**:801-807.
- 447 56. van der Meer JY, Poddar H, Baas BJ, Miao Y, Rahimi M, Kunzendorf A, van Merkerk R, Tepper PG,
448 Geertsema EM, Thunnissen AM, et al.: **Using mutability landscapes of a promiscuous**
449 **tautomerase to guide the engineering of enantioselective Michaelases.** *Nat Commun* 2016,
450 **7**:10911.
- 451 57. Sarkisyan KS, Bolotin DA, Meer MV, Usmanova DR, Mishin AS, Sharonov GV, Ivankov DN,
452 Bozhanova NG, Baranov MS, Soylemez O, et al.: **Local fitness landscape of the green**
453 **fluorescent protein.** *Nature* 2016, **533**:397-401.
- 454 58. Firnberg E, Labonte JW, Gray JJ, Ostermeier M: **A comprehensive, high-resolution map of a**
455 **gene's fitness landscape.** *Mol Biol Evol* 2014, **31**:1581-1592.
- 456 59. Li C, Qian W, Maclean CJ, Zhang J: **The fitness landscape of a tRNA gene.** *Science* 2016, **352**:837-
457 840.
- 458 60. Wrenbeck EE, Azouz LR, Whitehead TA: **Single-mutation fitness landscapes for an enzyme on**
459 **multiple substrates reveal specificity is globally encoded.** *Nat Commun* 2017, **8**:15695.
- 460 61. Jäckel C, Hilvert D: **Biocatalysts by evolution.** *Curr Opin Biotechnol* 2010, **21**:753-759.
- 461 62. Amitai G, Gupta RD, Tawfik DS: **Latent evolutionary potentials under the neutral mutational**
462 **drift of an enzyme.** *HFSP J* 2007, **1**:67-78.
- 463 63. Bloom JD, Romero PA, Lu Z, Arnold FH: **Neutral genetic drift can alter promiscuous protein**
464 **functions, potentially aiding functional evolution.** *Biol Direct* 2007, **2**:17.

64. Starr TN, Thornton JW: **Epistasis in protein evolution**. *Protein Sci* 2016, **25**:1204-1218.
65. Reetz MT, Kahakeaw D, Lohmer R: **Addressing the numbers problem in directed evolution**. *ChemBioChem* 2008, **9**:1797-1804.
66. Kiss G, Çelebi-Ölçüm N, Moretti R, Baker D, Houk KN: **Computational enzyme design**. *Angew Chem Int Ed* 2013, **52**:5700-5725.
67. Kries H, Blomberg R, Hilvert D: **De novo enzymes by computational design**. *Curr Opin Chem Biol* 2013, **17**:221-228.
68. Blomberg R, Kries H, Pinkas DM, Mittl PR, Grutter MG, Privett HK, Mayo SL, Hilvert D: **Precision is essential for efficient catalysis in an evolved Kemp eliminase**. *Nature* 2013, **503**:418-421.
69. Preiswerk N, Beck T, Schulz JD, Milovnik P, Mayer C, Siegel JB, Baker D, Hilvert D: **Impact of scaffold rigidity on the design and evolution of an artificial Diels-Alderase**. *Proc Natl Acad Sci USA* 2014, **111**:8013-8018.
70. Khare SD, Kipnis Y, Greisen P, Jr., Takeuchi R, Ashani Y, Goldsmith M, Song Y, Gallaher JL, Silman I, Leader H, et al.: **Computational redesign of a mononuclear zinc metalloenzyme for organophosphate hydrolysis**. *Nat Chem Biol* 2012, **8**:294-300.
71. Giger L, Caner S, Obexer R, Kast P, Baker D, Ban N, Hilvert D: **Evolution of a designed retro-aldolase leads to complete active site remodeling**. *Nat Chem Biol* 2013, **9**:494-498.
72. Obexer R, Studer S, Giger L, Pinkas DM, Grütter MG, Baker D, Hilvert D: **Active site plasticity of a computationally designed retro-aldolase enzyme**. *ChemCatChem* 2014, **6**:1043-1050.
73. Zeymer C, Zschoche R, Hilvert D: **Optimization of enzyme mechanism along the evolutionary trajectory of a computationally designed (retro-)aldolase**. *J Am Chem Soc* 2017, **139**:12541-12549.
74. Garrabou X, Beck T, Hilvert D: **A promiscuous de novo retro-aldolase catalyzes asymmetric michael additions via schiff base intermediates**. *Angew Chem Int Ed* 2015, **54**:5609-5612.
75. Garrabou X, Macdonald DS, Hilvert D: **Chemoselective Henry condensations catalyzed by artificial carboligases**. *Chemistry* 2017, **23**:6001-6003.
76. Garrabou X, Verez R, Hilvert D: **Enantiocomplementary synthesis of γ -nitroketones using designed and evolved carboligases**. *J Am Chem Soc* 2017, **139**:103-106.
77. Garrabou X, Wicky BI, Hilvert D: **Fast Knoevenagel condensations catalyzed by an artificial Schiff-base-forming enzyme**. *J Am Chem Soc* 2016, **138**:6972-6974.